Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Boston Common Asset Management LLC

Boston Common Asset Management LLC lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 21.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,353 shares of the medical equipment provider's stock after buying an additional 10,601 shares during the quarter. Boston Common Asset Management LLC's holdings in Zimmer Biomet were worth $6,831,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ZBH. Franklin Resources Inc. raised its holdings in shares of Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after buying an additional 2,796,372 shares during the period. Norges Bank purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at $216,223,000. Dodge & Cox increased its holdings in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after purchasing an additional 2,044,645 shares during the period. Nuveen Asset Management LLC raised its position in Zimmer Biomet by 191.8% in the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock valued at $146,763,000 after purchasing an additional 913,310 shares in the last quarter. Finally, Sound Shore Management Inc. CT acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $81,447,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Robert W. Baird reduced their price target on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Wells Fargo & Company reduced their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Royal Bank of Canada reduced their price target on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, Morgan Stanley reduced their price target on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $111.53.

Zimmer Biomet Stock Performance

NYSE:ZBH traded down $1.22 during mid-day trading on Friday, reaching $92.12. 3,505,131 shares of the stock were exchanged, compared to its average volume of 1,800,204. The company has a 50 day simple moving average of $99.99 and a 200-day simple moving average of $104.76. The stock has a market capitalization of $18.23 billion, a P/E ratio of 20.70, a P/E/G ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.92 and a 1 year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.94 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.04%. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.